Senti Biosciences, Inc. (NASDAQ:SNTI – Get Rating)’s share price traded up 2.2% during trading on Tuesday . The stock traded as high as $1.46 and last traded at $1.41. 28,020 shares traded hands during trading, a decline of 74% from the average session volume of 109,811 shares. The stock had previously closed at $1.38.
Wall Street Analyst Weigh In
SNTI has been the subject of a number of research reports. JPMorgan Chase & Co. initiated coverage on Senti Biosciences in a report on Friday, December 16th. They issued a “neutral” rating for the company. Morgan Stanley reduced their price objective on Senti Biosciences from $7.50 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, January 27th. Finally, Chardan Capital cut their target price on Senti Biosciences from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, January 27th.
Senti Biosciences Price Performance
The company has a fifty day moving average price of $1.65 and a 200-day moving average price of $2.06.
Institutional Inflows and Outflows
About Senti Biosciences
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
- Get a free copy of the StockNews.com research report on Senti Biosciences (SNTI)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.